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We describe the development of a capture enzyme-linked immunosorbent assay for the detection of the
dengue virus nonstructural protein NS1. The assay employs rabbit polyclonal and monoclonal antibodies as
the capture and detection antibodies, respectively. Immunoaffinity-purified NS1 derived from dengue 2 virus-
infected cells was used as a standard to establish a detection sensitivity of approximately 4 ng/ml for an assay
employing monoclonal antibodies recognizing a dengue 2 serotype-specific epitope. A number of serotype
cross-reactive monoclonal antibodies were also shown to be suitable probes for the detection of NS1 expressed
by the remaining three dengue virus serotypes. Examination of clinical samples demonstrated that the assay
was able to detect NS1 with minimal interference from serum components at the test dilutions routinely used,
suggesting that it could form the basis of a useful additional diagnostic test for dengue virus infection. Furthermore,
quantitation of NS1 levels in patient sera may prove to be a valuable surrogate marker for viremia. Surprisingly
high levels of NS1, as much as 15 mg/ml, were found in acute-phase sera taken from some of the patients
experiencing serologically confirmed dengue 2 virus secondary infections but was not detected in the convalescent
sera of these patients. In contrast, NS1 could not be detected in either acute-phase or convalescent serum samples
taken from patients with serologically confirmed primary infection. The presence of high levels of secreted NS1 in
the sera of patients experiencing secondary dengue virus infections, and in the context of an anamnestic
antibody response, suggests that NS1 may contribute significantly to the formation of the circulating immune
complexes that are suspected to play an important role in the pathogenesis of severe dengue disease.
Dengue viruses are a major public health problem in tropical
and subtropical areas, being the cause of one of the most
important mosquito-borne viral diseases. Up to 20 million peo-
ple are infected globally each year (15). Infection with dengue
virus can result in a relatively benign, acute febrile illness
(dengue fever) or in severe disease with abnormalities in vas-
cular permeability (dengue hemorrhagic fever [DHF]) which
can sometimes lead to sudden and often fatal hypovolemic
shock (dengue shock syndrome [DSS]) (10). All four dengue
virus serotypes are capable of causing dengue fever, with the
induction of an immune response that in most cases leads to
lifelong protection against clinical disease arising from infec-
tion with the homologous serotype. Secondary infection with a
heterologous serotype, however, may lead to the severe com-
plications of DHF and DSS. Antibody-dependent enhance-
ment of dengue virus growth in cells of the monocyte/macro-
phage lineage resulting from the presence of preexisting,
nonneutralizing dengue virus-specific antibodies has been pro-
posed as the pathogenetic mechanism that underlies DHF and
DSS (12). However, the link between this enhanced replication
and the vascular permeability that characterizes these diseases
is still the subject of conjecture (24).
The dengue viruses are enveloped and contain a single,
positive-sense RNA genome of about 11 kb that encodes a
large polyprotein precursor. Co- and posttranslational process-
ing gives rise to three structural and seven nonstructural pro-
teins, encoded by genes in the order (from 59 to 39) C, prM, E,
NS1, NS2a, NS2b, NS3, NS4a, NS4b, and NS5. NS1 is a 46- to
50-kilodalton glycoprotein which is expressed in both mem-
brane associated (mNS1) and secreted (sNS1) forms (5, 30)
and possesses both group-specific and type-specific determi-
nants (6, 14). NS1 is unusual for a viral glycoprotein in that it
does not form part of the virion structure but is expressed on
the surface of infected cells. NS1 is initially translocated into
the endoplasmic reticulum via a hydrophobic signal sequence
encoded in the C-terminal region of E, where it rapidly dimer-
izes (30). While the function of NS1 is yet to be fully defined,
preliminary evidence has shown it to be involved in viral RNA
replication (18, 19).
NS1 was first described as a soluble complement-fixing
(SCF) antigen in infected cell cultures (2, 3). The identity of
SCF as the viral-encoded 46-kilodalton glycoprotein gp46 was
established by Smith and Wright (28), and it was later renamed
NS1 following the sequencing of the yellow fever virus genome
(23). The flavivirus NS1 has been recognized as an important
immunogen in infections (26) and has been shown to play a
role in protection against disease (13, 27). However, a poten-
tial role for NS1 in immunopathogenesis has also been pro-
posed based on the finding of anti-SCF antibodies in sera from
patients undergoing secondary but not primary infections (8).
The contribution of this antibody response to disease severity
is not clearly understood, but it is now well established that
circulating immune complexes and complement activation are
integral features of DHF and DSS and are likely to play a
significant role in pathogenesis (11, 24, 29). It is possible,
therefore, that in addition to the virion itself (22), secreted
NS1 may also contribute to immune complex formation.
In this study, we used our existing panel of monoclonal
antibodies (MAbs) (6) to establish a sensitive capture enzyme-
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linked immunosorbent assay (ELISA) for NS1. Our aims were
to assess the potential of using NS1 as a diagnostic marker of
infection as well as to provide the assays necessary for inves-
tigating whether secreted NS1 might contribute to immune
complex formation. The assay developed in this study was able
to detect and quantify the levels of dengue 2 virus NS1 in both
tissue culture harvests and a small panel of patient sera.
MATERIALS AND METHODS
Cells and viruses. Vero cells were used to passage dengue viruses and were
grown in 199 medium (Gibco BRL, Melbourne, Australia) supplemented with
5% fetal calf serum. Dengue type 2 virus (PR159) was originally obtained from
Ernie Gould (Institute of Virology and Environmental Microbiology, NERC,
Oxford, United Kingdom), and dengue types 1 (Hawaii), 2 (NGC), 3 (H87), and
4 (H241) viruses were from John Aaskov (Queensland University of Technology,
Brisbane, Australia). Virus stocks were used to infect 80% confluent cell mono-
layers in 199 medium supplemented with 2% fetal calf serum and incubated at
37°C until cytopathic effect (CPE) was observed (between 3 and 6 days postin-
fection, depending on serotype), at which stage the supernatant and cell mono-
layers were harvested.
Immunoaffinity purification of NS1. Purification of the secreted form of NS1
(sNS1) from media harvests of infected Vero cells was carried out as previously
described by Falconar and Young (5). Briefly, harvests taken at peak CPE from
Vero cells infected with dengue 2 virus (NGC) at a multiplicity of infection of 0.1
were first clarified by centrifugation at 2,000 3 g in a bench-top centrifuge. After
the addition of protease inhibitors, the clarified supernatant was then passed
through a Sepharose 4B (Pharmacia, Uppsala, Sweden) column coupled with the
MAb 5H4.4 (6). After washing the column with 5-bed volumes of TNE (10 mM
Tris-HCl [pH 7.4], 150 mM NaCl, and 5 mM EDTA), sNS1 was eluted from the
column in TNE containing 40 mM diethylamine (BDH, Kilsyth, Australia).
Purity of the eluted fractions was assessed by sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis (SDS-PAGE) followed by silver staining. Peak frac-
tions were pooled, protein concentration was determined by the bicinchoninic
acid assay (Pierce), and fractions were stored as 50-ml aliquots at 270°C.
Monoclonal and polyclonal antibodies. Previously characterized MAbs (6)
raised against dengue 2 virus (PR159) NS1 were tested as probes for the capture
ELISA. A selection of these MAbs was then chosen for further analysis based on
preliminary binding data (Table 1). This selected panel includes both dengue
group cross-reactive and dengue 2-specific MAbs. All were prepared as ascitic
fluids by inoculation of hybridomas into pristane-primed mice and stored as 1:1
glycerol stocks at 220°C. Polyclonal, monospecific anti-NS1 antibody was raised
in rabbits hyperimmunized with immunoaffinity-purified, dimeric dengue virus
type 2 NS1. A human polyclonal serum with a high-titered anti-NS1 response was
obtained from a primary infection case some 3 months after infection.
ELISA capture assay. The wells of a microtiter plate (Immulon 4; Dynatech)
were coated with 50 ml of a 1:1,500 dilution of rabbit anti-NS1 serum in carbon-
ate buffer (pH 9.6) and incubated overnight at 4°C. Between all subsequent
incubation steps, the plates were washed three times with phosphate-buffered
saline (PBS) containing 0.05% Tween 20 (PBST), and all dilutions were made in
PBST containing 0.25% gelatin. The plates were blocked with 150 ml of PBS
containing 1% gelatin and incubated at room temperature for 1 h. The antigen
(immunoaffinity-purified NS1 or patient sera) was diluted in duplicate (in some
cases, normal human sera [NHS] was incorporated in the diluent), and after
removal of the blocking solution, 50 ml per well was added. The plates were
incubated at 37°C for 1 h and washed, and 50 ml of the anti-NS1 MAb (diluted
1:1,000) was then added. Following a further incubation at 37°C for 1 h, the
plates were washed and 50 ml of goat anti-mouse peroxidase-conjugated antibody
(Jackson Immunoresearch) diluted 1:1,000 was added. Plates were incubated for
1 h at 37°C, washed, and developed with freshly prepared substrate solution
(0.04% o-phenylenediamine.2HCl in citrate phosphate buffer, pH 5.0, containing
0.003% H2O2). The reaction was allowed to proceed in the dark for 10 min
before being halted by the addition of 25 ml of 2 M H2SO4 and read on a
microplate reader (MR5000; Dynatech Laboratories) at 490 nm.
Clinical samples. Sera from dengue virus-infected patients collected during
an epidemic in Thailand were kindly provided by C. Hoke and colleagues
(AFRIMS, Bangkok, Thailand). Paired serum samples taken from individuals
during the acute and convalescent phases of both primary and secondary dengue
infection were tested for the presence of NS1 by using the type-specific MAb
1H7.4 as a probe. Sera were initially diluted 1/10 and then serially diluted twofold
in the assay. Each microtiter plate included a titration of a standard preparation
of purified NS1 (over the range, 10 to 100 ng/ml) diluted in PBST containing a
1/10 dilution of NHS.
RESULTS
Selection of capture and detection antibodies. In order to
establish a sensitive antigen capture ELISA for the dengue
virus NS1 glycoprotein, we used a cross-reactive rabbit poly-
clonal antiserum raised against immunoaffinity-purified NS1 to
capture NS1 from all four dengue virus serotypes and exam-
ined a panel of 35 MAbs (6) as selective detection probes.
Checkerboard analyses of a dilution series of the rabbit anti-
serum against the full panel of MAbs and using a standard
concentration of immunoaffinity-purified NS1 established an
optimum dilution of 1:1,500 for the polyclonal capture anti-
body and 1:1,000 for those MAbs which yielded a signal in the
assay. Using any of the MAbs, either singly or in combination
as capture antibodies, resulted in a significantly reduced signal,
and only a limited number of MAbs were effective as detection
probes. Based on these results, a small panel of MAbs was chosen
for further analysis. These are listed in Table 1 and include those
recognizing both type-specific and cross-reactive epitopes.
Figure 1 shows the results of using these MAbs as detection
probes in the analysis of a dilution series of purified dengue 2
NS1. The results clearly indicate that the dengue 2-specific
MAbs, 5H4.4, 1H7.4, and 2C9.4, clustered as a group showing
the highest binding capacity. Not surprisingly, peptide-binding
and competition studies have mapped these MAbs to the same
epitope (25VHTWTEQYK33) (7, 31). The cross-reactive MAbs,
3D1.4, 3A5.4, and 4H3.4, also clustered as a group, reflecting
their common epitope specificity (111LRYSWKTWGKA121)
(7), and although less efficient as detection probes, they should
prove useful for the analysis of NS1 encoded by each dengue
virus serotype.
Given the identification of synergistic interactions between
selected MAbs in competition analyses (31), we examined the
effect of various combinations of MAbs on the detection sen-
sitivity of the assay. No improvement in detection was observed
with these cocktails when compared with 1H7.4 alone (results
not shown), so this MAb was chosen for further assessment.
Sensitivity and reproducibility of the assay. To determine
the sensitivity of the NS1 capture assay, replicates of serially
diluted immunoaffinity-purified NS1 of known concentration
were probed with 1H7.4 (Fig. 2). Both PBS and pooled NHS
were used as diluents in order to determine the effect that the
presence of serum may have on detection sensitivity. The effect
of NHS components on the capture and detection of NS1 was
minimal at a 1-in-5 dilution and negligible at a 1-in-10 dilution
TABLE 1. NS1-specific MAbs used as detection probes in the NS1
capture ELISA
MAba ELISAtiterb
Linear
epitopec
Cross-reactivity with other
dengue serotypesd
DEN1 DEN2 DEN3 DEN4
1H7.4 6.0 1 2 111 2 2
2C9.4 5.4 1 2 11 2 2
5H4.4 5.4 1 2 111 2 2
5H6.3 4.6 2 2 111 2 1
5B5.3 3.5 2 2 11 111 1
4H3.4 5.3 1 111 111 111 111
3D1.4 5.2 1 111 111 111 111
3A5.4 5.7 1 111 111 111 111
a All MAbs used in this study are of the immunoglobulin G1 isotype and were
described in detail by Falconar and Young (6).
b Titers are expressed as log10 50% end points, as measured against purified
NS1-coated ELISA plates.
c Reactivity of the MAbs with linear epitopes was determined by dot blot
analysis against reduced and carboxy-methylated, purified dengue 2 NS1. PEP-
SCAN analysis has identified the location of some of these epitopes and was
reported by Falconar et al. (7). See text for details.
d Cross-reactivities were determined by immunoblot analysis of SDS-PAGE-
separated SDS lysates of Vero cells infected with the dengue virus serotype
prototypes DEN1 (Hawaii), DEN2 (NGC), DEN3 (H87), and DEN4 (H241) and
given arbitrary values based on intensity of staining.
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(Fig. 2). As the subsequent analysis of patient sera was rou-
tinely carried out at dilutions of 1 in 10 or greater, it is assumed
that serum components at these concentrations have little or
no effect on detection sensitivity. The assay was considered
positive if a sample yielded an optical density (OD) reading 3
standard deviations (0.036 OD492 [optical density at 492 nm]
units) above the mean OD value for negative control samples
(0.122 6 0.012). Using these criteria, the limit of detection of
NS1 with MAb 1H7.4 was approximately 4 ng/ml. The limit of
detection of dengue 2 virus NS1 with the cross-reactive MAb
probe 3D1.4 was approximately 15 ng/ml (data not shown).
The reproducibility of the assay was examined with multiple
replicates assessed within the same test and by repeated testing
over a 2-month period. Not surprisingly, the coefficient of
variation results varied considerably depending on the level of
NS1 present in the samples. In subsequent analyses of patient
test sera (see below), samples were titrated and estimates of
NS1 levels were determined by comparison of absorbance
readings of appropriately diluted fractions with a standard
curve derived from a titration series of purified NS1, within the
range of 20 to 200 ng/ml. At a concentration of 100 ng/ml, the
coefficient of variation for 12 replicates tested in the same
assay was 4%, and the test-to-test coefficient of variation, using
16 replicates, was 12%. Samples stored at 270°C were stable
over several months (data not shown).
Comparison of type-specific and group-reactive MAbs in the
detection of secreted NS1 of all four dengue virus serotypes. In
order to examine the reactivity in the ELISA capture assay of
NS1 derived from each of the four dengue virus serotypes, we
tested media harvests taken from infected cell monolayers.
Media harvests were taken at peak CPE (ranging from day 5 to
9 days postinfection for the different serotypes) from separate
25-cm2 flasks of Vero cell cultures infected at a multiplicity of
infection of 0.1 with the four prototype dengue virus serotypes
(DEN1 Hawaii, DEN2 NGC, DEN3 H87, and DEN4 H214).
The 10-ml harvests were clarified by low-speed centrifugation
for 10 min prior to analysis of the resulting supernatant frac-
tions in the capture assay using either the type-specific (1H7.4)
or group-reactive (3D1.4) MAbs as detection probes (Fig. 3).
The specificity of the 1H7.4 probe for dengue 2 virus-derived
NS1 was clearly demonstrated in Fig. 3A, as was the increased
detection sensitivity of this MAb (approximately fourfold)
compared with that of 3D1.4 (Fig. 3B). Comparison with a
standard curve performed in parallel and prepared with serial
dilutions of purified dengue 2 virus NS1 of known concentra-
tion indicated that between 5 and 7 mg/106 cells of NS1 was
secreted from dengue 2 virus-infected Vero cells under these
conditions. A time course analysis of NS1 secretion from in-
fected cells paralleled virus titers as determined by a plaque
assay (data not shown), suggesting that it may be possible to
use secreted NS1 as a surrogate marker for viral infection.
It is not known whether 3D1.4 recognizes the NS1 species
derived from each serotype with equal avidity; however, it is
interesting that the reactivity profile demonstrated in Fig. 3B
reflects the antigenic pairings of the two known serotype sub-
groups, DEN2/4 and DEN1/3. It is also likely that the different
levels of detection are in part due to the binding characteristics
of the rabbit polyclonal capture antibody which was prepared
by immunization with purified dengue 2 virus NS1. Differences
FIG. 1. Reactivity of a panel of MAbs against serial dilutions of immunoaffinity-purified dengue 2 NS1 in the capture ELISA. NS1 was captured with ELISA plates
coated with a 1:1,500 dilution of rabbit anti-NS1 polyclonal antisera and subsequently probed with the MAbs at a dilution of 1:1,000.
FIG. 2. Effect of human serum components on the detection of NS1 in the
capture ELISA. Immunoaffinity-purified, secreted NS1 was serially diluted in the
absence (F) or presence of NHS at dilutions of 1 in 5 (D) and 1 in 10 (E) and
probed with the type-specific MAb 1H7.4. Data points represent the mean 6
standard deviation for four replicates. The dashed line is the mean for the
negative control samples (OD490, 0.122 6 0.012).
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in growth kinetics in Vero cells between the four dengue virus
serotypes will also contribute to the varying levels of antigen
detected in this assay. Currently, the assay employing 3D1.4 as
the detecting probe can only provide evidence of the presence
of NS1 in a sample. In order to provide quantitative estimates
of NS1 derived from all four serotypes, purified preparations of
each serotype NS1 will need to be generated to establish ap-
propriate standard curves.
Detection of NS1 in patient sera. In order to test the suit-
ability of the assay for quantifying NS1 in clinical samples, a
small panel of paired sera from dengue 2 virus-infected pa-
tients was examined. Sera taken during the acute phase of
infection from 22 patients as well as 2 weeks later, during
convalescence, were tested. Serum samples were serially di-
luted and processed in the ELISA capture assay (using 1H7.4
as the detecting antibody) in parallel with a titration of immu-
noaffinity-purified dengue 2 sNS1 as a standard. Absorbance
readings of those dilutions that fell within the straight-line
portion of the standard curve (10 to 100 ng/ml) were used to
calculate the serum NS1 concentration (Table 2). Six of the
patients were experiencing a primary infection with dengue 2
virus, and NS1 was not detected in any of the paired sera from
this group. Of the 16 patients with a serologically confirmed
secondary infection, seven were positive for NS1 with levels
ranging from 70 ng/ml to as high as 15 mg/ml in the acute-phase
sera. These values should be viewed in the context of the likely
presence of anti-NS1 antibodies in the acute-phase sera of
patients experiencing a secondary infection (4, 8, 17). They are
presumably an underestimate of the true levels of secreted
NS1, given that a significant proportion of NS1 may be trapped
in immune complexes and not detected in our assay. Indeed,
preincubation of purified NS1 with human sera containing
antibodies to NS1 successfully competes with all of the MAb
probes used in this assay (data not shown). We have tried a
number of techniques reported to successfully dissociate im-
mune complexes for subsequent antigen detection (16, 21), but
to date without success, as each appears to lead to significant
loss of NS1 antigenicity. None of the convalescent sera tested
positive for NS1 (Table 2), presumably reflecting the transient
nature of the viremia (9). Although there did not appear to be
a significant difference in either the detection or in the levels of
NS1 between those patients with dengue fever and those with
dengue hemorrhagic fever, the small sample size precludes any
definitive conclusions.
DISCUSSION
This paper describes the development of a capture ELISA
for detection of the dengue virus protein NS1. Screening of an
extensive panel of MAbs as detection probes and rabbit poly-
clonal anti-NS1 hyperimmune sera as capture antibody lead to
the optimization of both type-specific and serotype cross-reac-
tive assays. Despite the availability of a large number of MAbs
specific for both linear and conformational epitopes (6), the
majority were ineffective as probes in the capture ELISA. Of
interest was the finding that only those MAbs specific for linear
determinants, one type specific and the other cross-reactive
among the dengue viruses, were effective as detection probes.
The identity of these linear epitopes has been reported previ-
ously (7) and were defined by binding of the MAbs to a set of
overlapping peptides. Although the amino acid sequence of
the peptide identified by the dengue 2 virus-specific MAbs
(25VHTWTEQYK33) is shared by the other three virus sero-
types, the type specificity of their binding was clearly demon-
strated in the present study (Fig. 3A). This finding supports our
earlier demonstration that amino acids flanking this linear
epitope appear to contribute conformational constraints that
lead to the epitope specificity seen in the native protein (7).
The sensitivity of the dengue 2 virus type-specific assay was
estimated with immunoaffinity-purified NS1. Using this prep-
aration as a reference standard, the assay was able to detect
levels of NS1 down to 4 ng/ml. An analysis of infected Vero
cells revealed that up to 7 mg of NS1 per ml was secreted into
FIG. 3. Capture ELISA detection of NS1 secreted from Vero cells infected
with all four dengue virus serotypes. Type-specific (1H7.4) (A) and group-
reactive (3D1.4) (B) MAbs were used as the detection probes for media harvests
from DEN1- (l), DEN2- (F), DEN3- ( n ), and DEN4 ()-infected cells.
TABLE 2. NS1 levels in the sera of dengue 2 virus-infected
patients
Type of
infectiona Grade
b Serum phase
No. positive/
no. tested
(%)
[NS1] (mg/ml)c
Primary DF Acute 0/6 (0) —d
Convalescent 0/6 (0) —
Secondary DF Acute 2/5 (40) 0.6, 3.4
Convalescent 0/5 (0) —
Secondary DHF Acute 5/11 (45) 0.07, 0.9, 0.8, 2.4, 15.0
Convalescent 0/11 (0) —
a Defined by hemagglutination inhibition titers.
b DF, dengue fever; DHF, dengue hemorrhagic fever.
c NS1 levels were determined based on a comparison of the mean OD readings
of diluted serum samples (three replicates for each dilution) in the ELISA
capture assay with a standard curve performed in parallel.
d NS1 level is below the detection sensitivity of the assay (4 ng/ml).
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the media, with levels of secretion correlating with infectious
virus titer.
We next tested the levels of NS1 in a panel of patient sera
with the aim of assessing the potential of the capture ELISA as
a diagnostic assay as well as the value of using NS1 as a
surrogate marker of infection. However, in this study, NS1 was
not detected in the limited panel of sera taken from patients
experiencing a primary infection (Table 2). This result most
likely reflects the sensitivity of the assay rather than the ab-
sence of NS1 in these samples, given that secreted NS1 is
normally produced by infected eukaryotic cells and should
therefore be present during the viremic phase of infection (30).
The sensitivity of the assay will need to be improved beyond
the current limit of 4 ng/ml to detect what must be lower levels
of secretion of this protein in primary cases and in order for the
assay to be of value in the routine diagnosis of dengue virus
infections. These studies are currently underway. The low level
of NS1 in these sera correlates well with earlier observations
made by a number of groups of a poor antibody response to
NS1 in most cases of primary infection (4, 8, 17). In contrast to
these findings, relatively high levels of secreted NS1 were de-
tected in the acute sera of patients experiencing a secondary
infection (Table 2). This increase in the relative level of NS1 in
turn suggests an increase in the infected cell population and,
therefore, viral load in secondary versus primary infections.
Taken together, these data provide the first direct evidence for
enhanced virus replication in secondary infections in vivo, a
hypothesis that has previously been supported by largely cir-
cumstantial data (24). We are presently examining a more
extensive panel of patient sera to validate these preliminary
findings.
Numerous studies have shown that in secondary dengue
virus infections, both immune complexes and complement con-
sumption vary linearly with disease severity pointing to a clear
role for immune complexes in the pathogenesis of DHF and
DSS (1, 20, 24, 25, 29). However, the identity of the antigen(s)
involved in immune complex formation, while generally con-
sidered to be whole dengue virions (24), has yet to be deter-
mined. We have so far tested a relatively limited panel of
patient sera, and the availability of only paired sera means that
we have no data on the kinetics of appearance of NS1 and the
antibody response to it. Nevertheless, the presence of both
high levels of NS1 in the sera of secondarily infected patients,
coupled with a vigorous anamnestic anti-NS1 response (4, 8,
17), identifies NS1 as a candidate antigen responsible for the
formation of immune complexes in sufficient quantities to ex-
plain the massive complement activation seen in DHF and
DSS (11, 24). Studies which address this possibility are pres-
ently in progress.
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